Everolimus and tacrolimus Combo Safe with Better Kidney Outcomes in Pediatric Heart Transplants: JAMA
USA: Researchers have found in a new study that among 6-month pediatricheart transplantsurvivors,everolimuswith low-dose tacrolimus was as effective as tacrolimus with mycophenolate in preventing rejection, cardiac allograft vasculopathy (CAV), andchronic kidney disease(CKD) at 30 months. The everolimus regimen also appeared to be safe. It was associated with improved kidney function and a reduction incytomegalovirus(CMV) infections.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!